Associated Papers
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Non-V600E BRAF mutation in hairy cell leukemia variant.
Vijayanarayanan A et al.
Ejhaem, 2024
Non-canonical BRAF variants and rearrangements in hairy cell leukemia.
Langabeer SE
Oncology Research, 2024
Hairy cell leukaemia with unusual BRAF mutations.
Maitre E et al.
Journal of Cellular and Molecular Medicine, 2023
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q et al.
Frontiers in Bioengineering and Biotechnology, 2022
MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.
Chakraborty R et al.
Cold Spring Harbor Perspectives in Medicine, 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.
Louveau B et al.
Targeted Oncology, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
Deciphering the genotype and phenotype of hairy cell leukemia: clues for diagnosis and treatment.
Polderdijk MCE et al.
Expert Review of Clinical Immunology, 2019
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Wang Y et al.
Frontiers in Oncology, 2019
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.
Sheikine Y et al.
Jco Precision Oncology, 2018
Targeted/exome sequencing identified mutations in ten Chinese patients diagnosed with Noonan syndrome and related disorders.
Xu S et al.
Bmc Medical Genomics, 2017
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H et al.
Histopathology, 2016
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Xu N et al.
Oncotarget, 2016
The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.
Kiel C et al.
Elife, 2016
NFkB is activated by multiple mechanisms in hairy cell leukemia.
Nagel S et al.
Genes, Chromosomes & Cancer, 2015
Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma.
Jiang N et al.
Oncology Reports, 2014
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
Carlino MS et al.
British Journal of Cancer, 2014
Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.
Tschernitz S et al.
British Journal of Haematology, 2014
Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J et al.
Clinical Lung Cancer, 2014
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
Zanaruddin SN et al.
Plos One, 2013
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.
Sun D et al.
Translational Oncogenomics, 2012
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
Krakstad C et al.
Plos One, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D et al.
Bmc Cancer, 2010
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
Schulz AL et al.
Clinical Genetics, 2008
Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.
Rodriguez-Viciana P et al.
Methods in Enzymology, 2008
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.
Gripp KW et al.
American Journal of Medical Genetics. Part A, 2007
Development and applications of a BRAF oligonucleotide microarray.
Kim IJ et al.
The Journal of Molecular Diagnostics : Jmd, 2007
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
Rodriguez-Viciana P et al.
Science (new York, N.y.), 2006
BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
Hinselwood DC et al.
Electrophoresis, 2005
Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report.
Mohamed SF et al.
Case Reports in Oncology, 0